Dr. Michael G. Kharas is a Member of the Molecular Pharmacology Program at the Memorial Sloan-Kettering Cancer Center (New York, NY, USA) and associated with Centers for Hematological Malignancies, Stem Cell Biology, Cellular Engineering, Experimental Therapeutics and Tow Developmental Oncology. Dr. Kharas finished his postdoctoral training at Brigham and Women’s Hospital in Boston and studied how signaling pathways alters stem cell regulation with Drs. Gary Gilliland and George Daley. In 2011 he started his laboratory at MSK and focused on the controllers of cellular fate in the blood.
His laboratory has uncovered new RNA regulators and how they modulate self-renewal, cell-fate decisions, and differentiation in both normal blood development and in myeloid leukemia. Dr. Kharas has received recognition including the Leukemia Lymphoma Society Scholar Award and American Society of Hematology Scholar Award. His laboratory is developing inhibitors that block the function of RNA regulators as a new therapeutic strategy in leukemia.